Mavorixafor

Confirm delete?

Mavorixafor

Zoom

Cat No: 28439

Biochemicals - Receptor Pharmacology

Mavorixafor is a chemokine (C-X-C motif) receptor 4 (CXCR4) antagonist (IC50 = 13 nM in a radioligand binding assay).{45673} It is selective for CXCR4 over chemokine (C-C motif) receptor 1 (CCR1), CCR2b, CCR4, CCR5, CXCR1, and CXCR2 (IC50s = >10 µM fo...

This product can only be bought through Cayman Chemical. Please contact us.

Product Overview
Data
Downloads
About Cayman

Territorial Availability: Available through Bertin Technologies only in France

Synonyms:

N1-(1H-benzimidazol-2-ylmethyl)-N1-[(8S)-5,6,7,8-tetrahydro-8-quinolinyl]-1,4-butanediamine

Correlated keywords:

880549-30-4 690656-53-2 X 4P X4P001 4P001 AMD11070 AMD070 CXC CXCR-4 CC CCR-1 2b 5 2 R1 R2b R4 R5 R2 CCRFCEM 12 CHOK1 gp-120 HIV1 NL-4.3 MT4 P4MAGI

Product Overview:
Mavorixafor is a chemokine (C-X-C motif) receptor 4 (CXCR4) antagonist (IC50 = 13 nM in a radioligand binding assay).{45673} It is selective for CXCR4 over chemokine (C-C motif) receptor 1 (CCR1), CCR2b, CCR4, CCR5, CXCR1, and CXCR2 (IC50s = >10 µM for all). Mavorixafor reduces chemotaxis of CCRF-CEM T cells induced by chemokine (C-X-C motif) ligand 12 (CXCL12; IC50 = 19 nM).{45674} It inhibits fusion of CHO-K1 cells expressing gp120 to P4-P5 MAGI cells with an IC50 value of 1.5 nM. It decreases HIV-1 NL4.3 viral replication in MT-4 cells and isolated human peripheral blood mononuclear cells (PBMCs; IC50s = 2 and 9 nM, respectively).{45673}

Size	5 mg
Shipping	dry ice
CAS Number	558447-26-0
Molecular Formula	C₂₁H₂₇N₅
SMILES	NCCCCN(CC1=NC2=C(C=CC=C2)N1)[C@@H]3C4=NC=CC=C4CCC3
Molecular Weight	349,5
Formulation	A crystalline solid
Purity	≥95%
Custom Code	2933.59
UNSPSC code	12352100

Technical File

MSDS

Click here to ask for your quote and get 15% off Cayman's products.

Cayman Chemical's mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.

Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.

Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.

Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.

Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009

Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.